File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database

TitleThe Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database
Authors
Issue Date2019
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobp
Citation
Proceedings of the American Society for Radiation Oncology 61st Annual Meeting, Chicago, IL, USA, 15-18 September 2019. In International Journal of Radiation Oncology - Biology - Physics, 2019, v. 105 n. 1, Suppl., p. E549-E550, abstract no. 3264 How to Cite?
AbstractPurpose/Objective(s): It has been strongly suggested that radiation-induced lymphopenia is a significant negative prognostic factor in non-small cell lung cancer, but there are fewer data in small cell lung cancer (SCLC). Here, we hypothesized that the baseline lymphocyte and/or lymphocyte nadir during chemoradiotherapy for SCLC is associated with survival. Materials/Methods: This is a retrospective study from a single Institution. Patients with limited stage SCLC treated from 2013 to 2017 were included. Additional eligibility included treatment with definitive thoracic radiation therapy (with or without concurrent chemotherapy) and the availability of complete-blood-count data from baseline and at least two time points during radiotherapy. The primary endpoint was Overall Survival, analyzed using the Kaplan-Meier method and Cox proportional hazard model. All tests were 2-sided and p-value less than 0.05 was considered to be significant. Results: A total of 623 patients were included: 424 male,199 female. Median age 59 years (range18-86 years). Median follow-up was 36.4 months (range: 33.1-39.7 months). Univariate analysis demonstrated that age, gender, clinical stage, concurrent chemotherapy (versus sequential), the use of prophylactic cranial irradiation (PCI), and the baseline lymphocyte were significantly associated with OS. Baseline lymphocyte (HR = 0.74, p = 0.005) and lymphocyte nadir during the course of radiation therapy (HR = 0.39, p = 0.002) were significant factors for OS under univariate analysis. On multivariate Cox regression models, after adjusting for gender (female Vs. male: HR = 1.2, p=0.0081), age(HR = 1.021, p<0.0001), smoking history(HR = 1.313, p<0.0001), clinical stage (Stage I-II Vs. stage III HR = 1.667, p<0.0001), cycles of chemotherapy (HR = 1.14, p<0.0001), RT timing ( HR = 0.890, p<0.0001) and the receipt of PCI (HR = 0.44, p<0.0001), the baseline lymphocyte count (HR = 0.88, p=0.003), and lymphocyte nadir (HR = 0.45 p<0.0001) remained significant in predicting OS. Conclusion: Baseline lymphocyte and Lymphocyte nadir were significantly associated with survival in LS-SCLC patients treated with definitive chemoradiation therapy. This suggests that future research may focus on strategy to minimize lymphocyte reduction to improve survival.
DescriptionPoster Viewing Q&A Session
Persistent Identifierhttp://hdl.handle.net/10722/293750
ISSN
2021 Impact Factor: 8.013
2020 SCImago Journal Rankings: 2.117
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, W-
dc.contributor.authorBiswas, T-
dc.contributor.authorMulvihill, L-
dc.contributor.authorDowlati, A-
dc.contributor.authorMachtay, M-
dc.contributor.authorKong, FP-
dc.date.accessioned2020-11-23T08:21:16Z-
dc.date.available2020-11-23T08:21:16Z-
dc.date.issued2019-
dc.identifier.citationProceedings of the American Society for Radiation Oncology 61st Annual Meeting, Chicago, IL, USA, 15-18 September 2019. In International Journal of Radiation Oncology - Biology - Physics, 2019, v. 105 n. 1, Suppl., p. E549-E550, abstract no. 3264-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://hdl.handle.net/10722/293750-
dc.descriptionPoster Viewing Q&A Session-
dc.description.abstractPurpose/Objective(s): It has been strongly suggested that radiation-induced lymphopenia is a significant negative prognostic factor in non-small cell lung cancer, but there are fewer data in small cell lung cancer (SCLC). Here, we hypothesized that the baseline lymphocyte and/or lymphocyte nadir during chemoradiotherapy for SCLC is associated with survival. Materials/Methods: This is a retrospective study from a single Institution. Patients with limited stage SCLC treated from 2013 to 2017 were included. Additional eligibility included treatment with definitive thoracic radiation therapy (with or without concurrent chemotherapy) and the availability of complete-blood-count data from baseline and at least two time points during radiotherapy. The primary endpoint was Overall Survival, analyzed using the Kaplan-Meier method and Cox proportional hazard model. All tests were 2-sided and p-value less than 0.05 was considered to be significant. Results: A total of 623 patients were included: 424 male,199 female. Median age 59 years (range18-86 years). Median follow-up was 36.4 months (range: 33.1-39.7 months). Univariate analysis demonstrated that age, gender, clinical stage, concurrent chemotherapy (versus sequential), the use of prophylactic cranial irradiation (PCI), and the baseline lymphocyte were significantly associated with OS. Baseline lymphocyte (HR = 0.74, p = 0.005) and lymphocyte nadir during the course of radiation therapy (HR = 0.39, p = 0.002) were significant factors for OS under univariate analysis. On multivariate Cox regression models, after adjusting for gender (female Vs. male: HR = 1.2, p=0.0081), age(HR = 1.021, p<0.0001), smoking history(HR = 1.313, p<0.0001), clinical stage (Stage I-II Vs. stage III HR = 1.667, p<0.0001), cycles of chemotherapy (HR = 1.14, p<0.0001), RT timing ( HR = 0.890, p<0.0001) and the receipt of PCI (HR = 0.44, p<0.0001), the baseline lymphocyte count (HR = 0.88, p=0.003), and lymphocyte nadir (HR = 0.45 p<0.0001) remained significant in predicting OS. Conclusion: Baseline lymphocyte and Lymphocyte nadir were significantly associated with survival in LS-SCLC patients treated with definitive chemoradiation therapy. This suggests that future research may focus on strategy to minimize lymphocyte reduction to improve survival.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobp-
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physics-
dc.relation.ispartofThe American Society for Radiation Oncology 61st Annual Meeting-
dc.titleThe Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database-
dc.typeConference_Paper-
dc.identifier.emailKong, FP: kong0001@hku.hk-
dc.identifier.authorityKong, FP=rp02508-
dc.description.natureabstract-
dc.identifier.doi10.1016/j.ijrobp.2019.06.1281-
dc.identifier.hkuros319992-
dc.identifier.volume105-
dc.identifier.issue1, Suppl.-
dc.identifier.spageE549-
dc.identifier.epageE550-
dc.identifier.isiWOS:000485671501548-
dc.publisher.placeUnited States-
dc.identifier.issnl0360-3016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats